NCT07160985

Brief Summary

AI-driven health management tools can leverage continuous glucose monitoring (CGM), physical activity, and dietary data to provide real-time, individualized feedback, improving self-management and adherence. The X Life model integrates AI algorithms with wearable devices to dynamically adjust dietary and exercise recommendations. Preliminary user studies suggest good usability and user experience, with potential to promote positive behavior change. This trial aims to preliminarily evaluate whether the X Life AI system can improve glucose tolerance (measured by oral glucose tolerance test \[OGTT\] incremental area under the curve \[iAUC\]) in adults with prediabetes, providing effect size and protocol design reference for a future confirmatory randomized controlled trial. The investigators designed this trial with the assistance of a digital twin-based clinical research system (termed X Town).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
131

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 21, 2025

Completed
17 days until next milestone

Study Start

First participant enrolled

September 7, 2025

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 8, 2025

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 23, 2025

Completed
7 days until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2025

Completed
Last Updated

February 12, 2026

Status Verified

February 1, 2026

Enrollment Period

3 months

First QC Date

August 21, 2025

Last Update Submit

February 10, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in OGTT Glucose Incremental Area Under the Curve (iAUC)

    Difference between groups in the incremental area under the curve for plasma glucose concentration during a 2-hour oral glucose tolerance test (OGTT), calculated from measurements at 0, 60, and 120 minutes, adjusting for baseline values.

    Baseline and at the end of the 28-day intervention period.

Secondary Outcomes (8)

  • Change in OGTT Plasma Glucose Levels

    Baseline and at the end of the 28-day intervention period.

  • Change in Continuous Glucose Monitoring (CGM) Metrics

    Baseline (7-day run-in period) and during the 28-day intervention period.

  • Change in OGTT Plasma Insulin Levels

    Baseline and at the end of the 28-day intervention period.

  • Composite Body Composition Outcomes

    Baseline and at the end of the 28-day intervention period.

  • Composite Metabolic Parameters

    Baseline and at the end of the 28-day intervention period.

  • +3 more secondary outcomes

Study Arms (2)

X Life Lifestyle Guidance

EXPERIMENTAL
Other: AI-based Lifestyle Management

Standard Care

ACTIVE COMPARATOR
Other: Lifestyle Management

Interventions

Participants will receive guideline-based lifestyle counseling according to national prediabetes prevention guidelines, delivered via mobile terminal, without AI-generated recommendations.

Standard Care

Participants will use the X Life system for 28 days, receiving real-time, personalized dietary and exercise recommendations triggered by glucose level and activity tracker data. Participants can interact with the system by uploading meal images, physical activity data, and wearable-derived metrics.

X Life Lifestyle Guidance

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18-70 years
  • Prediabetes (per ADA or WHO criteria)
  • Stable lifestyle and body weight (±5%) for ≥3 months
  • Owns and can operate a smartphone
  • Able to understand and sign informed consent

You may not qualify if:

  • Current glucose-lowering medication use
  • Severe cardiovascular disease, liver/kidney dysfunction, or active malignancy
  • Psychiatric or cognitive disorders affecting participation
  • Planned major surgery or long-distance travel during the study
  • Allergy/intolerance to CGM sensor materials

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shanghai Sixth People's Hospital

Shanghai, China

Location

MeSH Terms

Conditions

Glucose Intolerance

Condition Hierarchy (Ancestors)

HyperglycemiaGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

August 21, 2025

First Posted

September 8, 2025

Study Start

September 7, 2025

Primary Completion

November 23, 2025

Study Completion

November 30, 2025

Last Updated

February 12, 2026

Record last verified: 2026-02

Locations